Helsinn Healthcare S.A. v. Aurobindo Pharma Ltd. et al.

I'll research this case using targeted searches.

I'll research this case systematically, starting with the docket and core case documents.

Now let me pull the full docket and the key substantive orders.

Helsinn Healthcare S.A. v. Aurobindo Pharma Ltd., No. 1:13-cv-00688-GMS (D. Del.)

Bottom line: This was the Aurobindo/AuroMedics branch of Helsinn's multi-front Aloxi® (palonosetron HCl IV solution) ANDA campaign. It never reached trial or a merits ruling. After consolidation with three other Delaware ANDA cases, a February 2015 Markman hearing that resolved one disputed term by concession and deferred another to trial, and a wave of 2015 IPR petitions against the later-issued family members, every defendant settled. Two consent judgments were entered 2015-10-26, terminating the case. There is no verdict, no claim construction opinion on the merits, no JMOL/fee decision, and no appeal.

Note on the caption: the docket is now styled Helsinn Healthcare SA v. Cipla Ltd. (CourtListener docket 4220119) because Cipla was the last remaining defendant at termination; the case began against Aurobindo. Also, the metadata supplied to me lists only the '725 patent, but the '725 was one of three patents asserted at filing and one of five ultimately in suit.

---

1. Filing and initial pleadings (2013)

Parallel/related Delaware actions (later consolidated into 13-688): No. 13-1612 (Ben Venue/Bedford, filed 2013-09-25); No. 13-2101 (Accord/Intas, filed 2013-12-27); No. 14-427 (Cipla Ltd./Cipla USA). Mylan Inc./Mylan Institutional (No. 14-709) was also brought into the consolidated proceeding.

Scheduling (2014-01-09): claim construction opening briefs 4/17/2014; fact discovery cut-off 8/15/2014; expert discovery 1/12/2015; Markman 7/14/2014; pretrial conference 3/3/2015; 5-day bench trial set for 2015-03-16. Case referred to Magistrate Judge Mary Pat Thynge for ADR/mediation. Protective Order entered 2014-03-17 (D.I. 44). The schedule slipped repeatedly, ultimately pushing trial to 2015-11-02.

---

2. Consolidation and reshaping of the patent set (2014)

By stipulation (D.I. 26

I'll research the docket and counsel records for this case.

Let me pull the docket entries for the pro hac vice admissions and the original complaint's signature block.

Now let me verify the pro hac vice admissions and the docket's attorney listings, plus check for later additions to the trial team.

Counsel of Record — Plaintiff Side

Helsinn Healthcare S.A. v. Aurobindo Pharma Ltd., No. 1:13-cv-00688-GMS (D. Del.)

Threshold note on the plaintiff side: the case metadata lists only Helsinn, but the operative pleadings in 13-688 name two plaintiffs — Helsinn Healthcare S.A. and Roche Palo Alto LLC (Roche co-owned the palonosetron formulation patents). Helsinn and Roche had separate counsel: Helsinn was represented by Paul Hastings (N.Y.) with Morris Nichols as Delaware counsel; Roche was represented separately by Loeb & Loeb. Both sets of counsel are therefore "plaintiff-side" counsel of record, and I've flagged the distinction below.

Also note the docket is titled Helsinn Healthcare SA v. Cipla Ltd. on CourtListener/PACER because 13-688 became the lead consolidated case for Helsinn's Delaware ALOXI® ANDA suits (13-688, 13-1612, 13-2101, 14-427, 14-709), and Cipla, Mylan, Accord, Ben Venue/Eurohealth/West-Ward and others were swept in by amendment. The original April 2013 complaint was against Aurobindo only.

---

A. Delaware counsel of record (local counsel) — Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE

(Sources: D.I. 1 signature block; D.I. 16; D.I. 26; D.I. 49; D.I. 70; D.I. 99; D.I. 119 — all available on CourtListener's docket for No. 1:13-cv-00688.)

---

B. Helsinn's substantive/trial counsel (of counsel) — Paul Hastings LLP, 75 East 55th Street, New York, NY

These attorneys appeared "OF COUNSEL" on the complaints and briefs and were admitted pro hac vice. The pro hac vice motion on the docket (recorded between the Feb. 11, 2014 answer and the Mar. 4, 2014 answer) sought admission of O'Malley, Wexler, Dittmann, Conca, Young J. Park, Ji, Angela A. Ni, and Dana Weir; I did not retrieve the granting order itself, so treat the admission as highly likely but not independently confirmed.

---

C. Counsel for co-plaintiff Roche Palo Alto LLC — Loeb & Loeb LLP, 345 Park Avenue, New York, NY

---

D. What I could not verify

• In-house counsel: no Helsinn or Roche in-house attorney appears in any signature block or PHV motion I found. Helsinn is a small Swiss pharma; I found no evidence of an in-house appearance in 13-688 — but absence from the documents I could retrieve is not proof.
• Exact PHV order date/D.I. number in 13-688, and whether Karen Jacobs formally entered an appearance in that docket (versus appearing only on related filings).
• Sealed filings: the case has sealed/redacted claim-construction materials (e.g., D.I. 70 filed under seal July 8, 2014, redacted July 15, 2014), but counsel identity is fully visible on the public filings, so the sealed material does not obscure who represented the plaintiffs.
• The 2015 termination: the metadata shows termination 10/26/2015; I did not retrieve the dismissal/consent-judgment entry in this docket, so I'm not characterizing the settlement terms.

E. Important cross-check: Finnegan did not appear in this case

Several databases and secondary sources associate Helsinn with Finnegan, Henderson, Farabow, Garrett & Dunner. In this D. Del. action, Finnegan appears only in the parallel PTAB proceedings (Thomas L. Irving as back-up counsel in Helsinn's IPRs). Finnegan's Adam M. Stock still appears on Helsinn-side ALOXI®-family matters elsewhere, but no Finnegan attorney signed a filing in 1:13-cv-00688. Likewise, Kannon Shanmugam (Paul Hastings, Washington, D.C.) argued Helsinn v. Teva at the Supreme Court — same firm, but not counsel of record in this 2013 ANDA case, so I have not listed him.

Primary sources: CourtListener docket No. 4220119 (D. Del. 1:13-cv-00688), including D.I. 1, 16, 26, 49, 70, 99, 119 (https://www.courtlistener.com/docket/4220119/helsinn-healthcare-sa-v-cipla-ltd/); the 2014 stipulation PDF at https://storage.courtlistener.com/recap/gov.uscourts.ded.51743.99.0.pdf; the claim-construction brief at https://storage.courtlistener.com/recap/gov.uscourts.ded.51743.119.0.pdf; and Helsinn's IPR2015-01554 "Related Matters" filing identifying lead/back-up PTAB counsel.

I'll research the defense-side counsel of record for this case. Let me start with the docket and related sources.

Let me pull the actual docket from CourtListener and search for defense counsel appearances.

Good leads. Let me confirm the Aurobindo defense team details and the consolidated co-defendants' counsel.

Counsel of Record — Defendants

Scope/record caveat up front. This case's docket (CourtListener No. 4220119; consolidated proceeding No. 51743) does not contain a formal "appearance" for every defense lawyer, and Aurobindo's in-house counsel never appeared on the record. The names below are drawn from signed filings in the docket (answers, notices of service, stipulations, joint claim construction papers) and from the signature blocks that identify who was actually practicing in the case. Where I could not verify a name against a filed document, I say so rather than guess. Note also that the 2013–2015 defense team is not the team in later Helsinn/palonosetron matters (e.g., the 2022 Aurobindo representation by Morris James's Cortlan Hitch with Sterne Kessler's Sasha Rao, or the Greenberg Traurig and Wiggin and Dana appearances in other Aurobindo matters) — those are different cases and should not be imported here.

---

1. Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. / AuroMedics Pharma LLC (the defendants named in the complaint)

The defense was structured the standard D. Del. way: a Wilmington firm as local counsel of record filing everything, with a Washington, D.C. IP boutique as lead substantive counsel.

Unverified: No in-house attorney for Aurobindo or AuroMedics appears on the public docket; ANDA-house counsel participation, if any, is not reflected in filed documents. I also did not locate the specific pro hac vice motions for the Sterne Kessler team (the only PHV motion I could confirm from the docket text is Helsinn's, filed 2014-02-20 for its Paul Hastings team) — the PHV admissions for Sabharwal/Desai presumably exist but I could not pin the docket numbers.

---

2. Counsel for the other (consolidated) defendants

Because the '688 action was consolidated with the Ben Venue/Bedford, Accord/Intas, Cipla and Mylan matters, these attorneys were formally "defense counsel in the case" even though they did not represent Aurobindo. Given that the docket is now captioned in Cipla's name, the Cipla line is the most material of these.

---

3. Points to carry forward into the case narrative

• The defense had a single, stable team from 2013 through termination. Matterer/Herrmann (Morris James) as local counsel and Sabharwal/Desai (Sterne Kessler) as lead counsel appear continuously from the 2013 answer through the December 2014 claim construction briefing. There is no substitution of counsel on the record that I found — so the same team was in place when the October 26, 2015 consent judgments ended the case.
• This confirms the case was a genuinely litigated ANDA defense, not a default or paper defense. The Aurobindo defendants answered and counterclaimed for invalidity and noninfringement in August 2013, re-pleaded after the October 2013 and January 2014 amended complaints, served Rule 26 disclosures, and participated in claim construction briefing and the February 2015 Markman argument — all before settling.
• Consistency with the earlier sections: nothing here contradicts the prior narrative. It does, however, reinforce the caption caveat already flagged — the final-period docket name (Cipla) reflects only who was last standing, and Cipla's Leydig Voit team was never counsel for the originally named Aurobindo defendants.
• Litigation-posture footnote for the settlement analysis: because Aurobindo's invalidity case was being advanced by Sterne Kessler — the same firm that was simultaneously filing the 2015 IPR petitions against the later palonosetron family members on behalf of generics — the Delaware defense and the PTAB track were run out of the same firm, which is useful context for why the 2015 settlements came when they did.

Sources: D. Del. C.A. No. 13-688 docket (CourtListener docket 4220119, consolidated docket 51743), including D.I. 12 (Aug. 23, 2013 Answer), D.I. 36 (Feb. 11, 2014 Answer), the Feb. 6, 2014 Notice of Service of Aurobindo/AuroMedics Rule 26(a)(1) disclosures, D.I. 27 (June 2014 consolidation stipulation, all defendants' signature blocks), the Dec. 5, 2014 joint claim construction filing in the consolidated action (Sterne Kessler block for Aurobindo/AuroMedics), and the July 11, 2014 stipulation signed by Morris James for Aurobindo/AuroMedics; Federal Circuit No. 15-1700 (Sept. 9, 2015) and No. 12-1359 for Sabharwal/Desai practice history.